The 10 analysts offering 12-month price forecasts for Aldeyra Therapeutics Inc have a median target of 25.50, with a high estimate of 32.00 and a low estimate of 16.00. The median estimate represents a +214.04% increase from the last price of 8.12.
The current consensus among 10 polled investment analysts is to Buy stock in Aldeyra Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.26
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.